[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Alfredo M [@AlfredoM617](/creator/twitter/AlfredoM617) on x XXX followers Created: 2025-07-14 19:36:06 UTC VK2809: A Potential Breakthrough in NASH and Cardiometabolic Disease $VKTX While VK2735 leads headlines, VK2809 deserves its own spotlight. This is a liver-selective thyroid hormone receptor-β (TRβ) agonist developed for nonalcoholic steatohepatitis (NASH), a chronic, progressive liver disease with no FDA-approved drug. Phase 2b Results: Arguably Best-in-Class In its 52-week VOYAGE trial, VK2809 hit multiple histological and metabolic endpoints: XX% achieved NASH resolution (vs XX% placebo) XX% showed fibrosis improvement (vs XX% placebo) XX% achieved both — a rare dual endpoint success LDL and triglyceride reductions: Up to 25%, providing cardiovascular benefits beyond the liver Tolerability: No severe GI or systemic AEs, no discontinuation imbalance, and no liver toxicity This rivals, or exceeds Madrigal’s resmetirom, the current leader in NASH, and could position VK2809 as a second-in-class agent with better lipid effects. Importantly, Viking has expressed openness to partnering VK2809, recognizing the massive size and cost of NASH Phase X trials. That could unlock non-dilutive capital while retaining downstream economics. XXX engagements  **Related Topics** [voyage](/topic/voyage) [$vktx](/topic/$vktx) [Post Link](https://x.com/AlfredoM617/status/1944843363745980647)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Alfredo M @AlfredoM617 on x XXX followers
Created: 2025-07-14 19:36:06 UTC
VK2809: A Potential Breakthrough in NASH and Cardiometabolic Disease $VKTX
While VK2735 leads headlines, VK2809 deserves its own spotlight. This is a liver-selective thyroid hormone receptor-β (TRβ) agonist developed for nonalcoholic steatohepatitis (NASH), a chronic, progressive liver disease with no FDA-approved drug.
Phase 2b Results: Arguably Best-in-Class In its 52-week VOYAGE trial, VK2809 hit multiple histological and metabolic endpoints:
XX% achieved NASH resolution (vs XX% placebo)
XX% showed fibrosis improvement (vs XX% placebo)
XX% achieved both — a rare dual endpoint success
LDL and triglyceride reductions: Up to 25%, providing cardiovascular benefits beyond the liver
Tolerability: No severe GI or systemic AEs, no discontinuation imbalance, and no liver toxicity
This rivals, or exceeds Madrigal’s resmetirom, the current leader in NASH, and could position VK2809 as a second-in-class agent with better lipid effects.
Importantly, Viking has expressed openness to partnering VK2809, recognizing the massive size and cost of NASH Phase X trials. That could unlock non-dilutive capital while retaining downstream economics.
XXX engagements
